Browsing Over 990 Presentations

Sort By

Introduction of Speaker (ID 1789)

Q&A (ID 1794)

ESMO Colloquium supported by Lilly Oncology: Biomarker-driven treatment decision in metastatic NSCLC ESMO Colloquium

EGFR mutant mNSCLC: Single agent or in combination?

Lecture Time
01:15 PM - 01:40 PM
Session Name
ESMO Colloquium supported by Lilly Oncology: Biomarker-driven treatment decision in metastatic NSCLC
Speakers
  • Fabrice Barlesi
Location
Hall 407, Singapore, Singapore, Singapore
Date
Fri, 22.11.2019
Time
12:45 PM - 02:15 PM
Authors
  • Fabrice Barlesi

Singapore’s journey with precision oncology (ID 1799)

Q&A (ID 1804)

Navigating the waters of ES-SCLC (ID 1781)

Q&A (ID 1787)

Presentation of real world outcomes in ER+ HER2- mBC (ID 1792)

Generating meaningful evidence with novel trial designs and real-world data (ID 1797)

The landscape and role of IO-Chemo combination in NSCLC treatment (ID 1802)

ESMO Colloquium supported by Lilly Oncology: Biomarker-driven treatment decision in metastatic NSCLC ESMO Colloquium

Conclusion

Lecture Time
02:05 PM - 02:10 PM
Session Name
ESMO Colloquium supported by Lilly Oncology: Biomarker-driven treatment decision in metastatic NSCLC
Location
Hall 407, Singapore, Singapore, Singapore
Date
Fri, 22.11.2019
Time
12:45 PM - 02:15 PM

Introduction (ID 1779)